GURU.Markets stock price, segment price, and overall market index valuation
The company's share price ARS Pharmaceuticals
ARS Pharmaceuticals is developing an epinephrine nasal spray as an alternative to EpiPen. Its stock price is driven by news about the FDA approval process. The chart is a classic biotech story, where regulatory decisions can cause stocks to rise or fall.
Share prices of companies in the market segment - Pharma other
ARS Pharma is a pharmaceutical company that developed an over-the-counter nasal spray containing epinephrine for the treatment of severe allergic reactions. We classify it in the Pharma Other sector, and the chart below reflects industry dynamics and the FDA approval history for its product.
Broad Market Index - GURU.Markets
ARS Pharmaceuticals is a biopharmaceutical company that developed neffy, the first adrenaline nasal spray for the treatment of severe allergic reactions. As part of the GURU.Markets index, it represents the emergency medicine sector. The chart below represents the entire market. See how this innovator compares to the overall trend.
Change in the price of a company, segment, and market as a whole per day
SPRY - Daily change in the company's share price ARS Pharmaceuticals
For ARS Pharmaceuticals, a biopharmaceutical company, change_co is a measure of the sector's inherently high volatility. Each daily change reflects sensitivity to news about regulatory decisions regarding its drugs. This metric isn't just noise, but a critical component of the models on System.GURU.Markets that assess biotech risk.
Daily change in the price of a set of shares in a market segment - Pharma other
ARS Pharmaceuticals, Inc. is a pharmaceutical company. This chart highlights the sector's high volatility. Comparing it to SPRY, which is focused on developing an allergy nasal spray, helps assess its risk relative to more diversified pharmaceutical companies.
Daily change in the price of a broad market stock, index - GURU.Markets
ARS Pharmaceuticals is a biopharmaceutical company developing a nasal spray for the treatment of severe allergic reactions. The biotech sector is extremely volatile. The chart below reflects the average fluctuations in this industry, providing context for evaluating ARS stock.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization ARS Pharmaceuticals
ARS Pharma is a pharmaceutical company developing new drugs. Its shares, like many in the sector, are volatile and react to news about clinical trials. These scientifically driven movements are part of the complex and diverse landscape of the entire stock market.
Annual dynamics of market capitalization of the market segment - Pharma other
ARS Pharmaceuticals, Inc. is a biopharmaceutical company that developed the first nasal spray for the treatment of severe allergic reactions. Its stock performance is entirely dependent on the successful commercialization of this breakthrough product. The chart below shows how the market views its potential to change the standard of care.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
ARS Pharmaceuticals is a biopharmaceutical company whose stock performance is driven by the commercialization of its allergy nasal spray and progress in research. The company's business is not dependent on economic cycles. This chart reflects biotech events, not macroeconomic data.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization ARS Pharmaceuticals
ARS Pharma, a biopharmaceutical company, depends on its product cycle for its market capitalization. Monthly fluctuations on the chart reflect news related to FDA approval and the commercial launch of its flagship product, an epinephrine nasal spray, the success of which determines its future.
Monthly dynamics of market capitalization of the market segment - Pharma other
Biopharmaceutical companies developing breakthrough products, such as needle-free injections, are evaluated based on their market-changing potential. The dynamics of this sector, shown in the chart, reflect investor expectations regarding regulatory decisions. ARS Pharmaceuticals is operating in this context, awaiting the FDA's verdict.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
ARS Pharmaceuticals is developing an intranasal spray for allergic reactions. The company's stock is betting on the approval and commercial success of a single product. Its performance is entirely dependent on FDA news and doesn't correlate with overall market trends.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization ARS Pharmaceuticals
Shares of ARS Pharma, which is developing an adrenaline nasal spray, are experiencing high weekly volatility due to the FDA approval process. Any news from the regulator, requests for additional data, or announcements from competitors cause sharp price surges.
Weekly dynamics of market capitalization of the market segment - Pharma other
ARS Pharmaceuticals and the entire late-stage biotech sector are driven by a shared anticipation of regulatory decisions. FDA news is a key driver for everyone. The chart will show how the company fares in this volatile market.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
ARS Pharmaceuticals shares, like many biotechs, often move independently of the broader market. Their weekly performance is determined by FDA news, not macroeconomics. The chart shows moments when the company's shares completely defied the overall market trend.
Market capitalization of the company, segment and market as a whole
SPRY - Market capitalization of the company ARS Pharmaceuticals
ARS Pharmaceuticals' market capitalization chart visualizes the hopes for the first needle-free treatment for severe allergic reactions. It reflects investor valuations of its adrenaline spray, Neffy. Its dynamics reflect the company's interactions with the FDA and its potential to change the standard of care for anaphylaxis for millions of people.
SPRY - Share of the company's market capitalization ARS Pharmaceuticals within the market segment - Pharma other
ARS Pharmaceuticals is developing an intranasal epinephrine spray for the treatment of severe allergic reactions (anaphylaxis), offering a needle-free alternative to the EpiPen. Its market share is based on this breakthrough product. The chart shows how the market views its chances of changing the paradigm of emergency allergy care.
Market capitalization of the market segment - Pharma other
ARS Pharmaceuticals is developing an intranasal adrenaline spray for the treatment of severe allergic reactions. The chart below shows the overall market capitalization of the pharmaceutical sector, reflecting the search for more convenient and faster solutions. ARS's product could become a revolutionary alternative to traditional epipens.
Market capitalization of all companies included in a broad market index - GURU.Markets
The biotechnologies visible in the chart can offer simple solutions to serious problems. ARS Pharmaceuticals is developing adrenaline as a nasal spray for the treatment of severe allergic reactions. Its capitalization is a bet that this convenient product will replace traditional injections.
Book value capitalization of the company, segment and market as a whole
SPRY - Book value capitalization of the company ARS Pharmaceuticals
ARS Pharma's book value represents capital for the development of a needle-free alternative to EpiPen. At the clinical trial stage, the company's assets are primarily cash. The chart shows the financial reserve allocated to R&D and obtaining approval for the adrenaline nasal spray.
SPRY - Share of the company's book capitalization ARS Pharmaceuticals within the market segment - Pharma other
ARS Pharmaceuticals, a biopharmaceutical company, is on the verge of commercializing its product. Its share of the sector's assets, consisting of R&D capacity, is currently small, but will grow with the creation of manufacturing and distribution infrastructure for its epinephrine intranasal spray.
Market segment balance sheet capitalization - Pharma other
ARS Pharmaceuticals is developing a nasal spray for allergies. Pharmaceuticals, as the graph shows, are both knowledge- and capital-intensive. ARS is an R&D company; its capital lies not in its factories, but in the intellectual property it holds for its patient-friendly product.
Book value of all companies included in the broad market index - GURU.Markets
ARS Pharmaceuticals is developing an intranasal epinephrine spray for the treatment of severe allergic reactions. The company's book value represents the capital it is investing in obtaining FDA approval and preparing for the commercial launch of this potentially life-saving product.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - ARS Pharmaceuticals
ARS Pharmaceuticals is a pharmaceutical company. Its entire market capitalization is a premium to its cash flow. This premium is investors' bet that its epinephrine spray will be approved and become a new standard for treating anaphylaxis.
Market to book capitalization ratio in a market segment - Pharma other
ARS Pharmaceuticals is developing an intranasal adrenaline spray for the emergency treatment of severe allergic reactions. This represents a potential medical breakthrough. The chart shows how highly the market values this innovation and its market potential compared to the company's current book value.
Market to book capitalization ratio for the market as a whole
ARS Pharmaceuticals is developing an intranasal epinephrine spray as an alternative to EpiPen for the treatment of severe allergic reactions. Given the average market valuations shown in this chart, its assessment is based on the product's enormous potential, but also on the risks associated with obtaining final FDA approval.
Debts of the company, segment and market as a whole
SPRY - Company debts ARS Pharmaceuticals
ARS Pharmaceuticals is a pharmaceutical company developing an intranasal epinephrine spray as an alternative to injections for severe allergic reactions. During the pre-commercialization phase, the company incurs expenses for clinical trials and preparation for launch. This chart illustrates how the company is funding these critical stages of product launch.
Market segment debts - Pharma other
ARS Pharmaceuticals is a biopharmaceutical company on the cusp of commercializing its flagship product, a nasal spray for severe allergic reactions. The transition from R&D to sales requires significant investment in marketing and manufacturing. This chart shows how the company is funding this critical phase of its development.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio ARS Pharmaceuticals
ARS Pharmaceuticals is developing an intranasal epinephrine spray. This chart shows how the company is funding its path to commercialization. For a biopharma without revenue, debt is a bet on future regulatory approval. It carries significant risks, but if successful, it allows shareholders to retain a larger stake in the company than through a share issue.
Market segment debt to market segment book capitalization - Pharma other
ARS Pharmaceuticals is developing an intranasal epinephrine spray as an alternative to injections for severe allergic reactions. Biopharmaceuticals require significant investment before receiving regulatory approval. This chart shows the overall debt burden in the industry, allowing one to assess how the company is funding its clinical trials and preparations for market launch.
Debt to book value of all companies in the market
ARS Pharmaceuticals, Inc. is developing an epinephrine intranasal spray as an alternative to EpiPen. As it moves toward approval and commercialization, the company faces significant expenses. This chart shows the general financing terms, helping to understand which route—equity or debt—is most accessible to ARS at this critical stage.
P/E of the company, segment and market as a whole
P/E - ARS Pharmaceuticals
This metric for ARS Pharmaceuticals reflects expectations surrounding the launch of its core product, a nasal allergy spray. The company's P/E, if it is established, will be based on future sales projections and market share capture. It is an assessment of the commercial potential of a single key drug.
P/E of the market segment - Pharma other
ARS Pharmaceuticals is a biopharmaceutical company that developed neffy, an intranasal epinephrine spray for the emergency treatment of severe allergic reactions (anaphylaxis). This chart shows the average rating for the biotech sector. It helps assess the market's perception of the product's potential as a convenient alternative to EpiPen.
P/E of the market as a whole
ARS Pharmaceuticals is developing an intranasal epinephrine spray for the treatment of severe allergic reactions, which could become an alternative to EpiPen. Its valuation depends entirely on regulatory approval and the commercial success of this single product. The overall market sentiment reflected in this chart is completely irrelevant.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company ARS Pharmaceuticals
ARS Pharmaceuticals is developing an intranasal epinephrine spray for the treatment of severe allergic reactions (anaphylaxis) as an alternative to injections. The company's valuation depends on regulatory approval and the product's commercial success. This chart shows how much investors believe in the upcoming blockbuster, valuing the company based on projected sales.
%20P%2FE%20ARS%20Pharmaceuticals&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-ARS-Pharmaceuticals&v=1772513490962 "Chart of the company's future (projected) P/E ARS Pharmaceuticals")
Future (projected) P/E of the market segment - Pharma other
ARS Pharmaceuticals is developing an epinephrine nasal spray (neffy) for the emergency treatment of severe allergic reactions. This chart shows the overall profitability expectations for the pharmaceutical sector. SPRY's position relative to the average reflects the extent to which investors believe their product will become a convenient and preferable alternative to EpiPen injections.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Pharma%20other&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Pharma-other&v=1772513490985 "Future (projected) P/E graph of the market segment - Pharma other")
Future (projected) P/E of the market as a whole
ARS Pharmaceuticals is developing an intranasal epinephrine spray for the treatment of severe allergic reactions. As a biopharmaceutical company in the commercialization stage, its success depends on regulatory approval and market demand. This sentiment curve influences investor willingness to fund the new product's market launch.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772513491016 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit ARS Pharmaceuticals
ARS Pharmaceuticals is developing an intranasal epinephrine spray (neffy) for the treatment of severe allergic reactions. Being in the pre-commercialization stage, its financial graph primarily shows losses from investments in research and FDA approval. Future profits depend on the success of the product launch.
Profit of companies in the market segment - Pharma other
ARS Pharmaceuticals is developing an intranasal epinephrine spray for the treatment of severe allergic reactions, which could become an alternative to injections. The company's success depends on regulatory approval. This chart shows the overall profitability of its pharmaceutical segment. It illustrates the industry's success in creating and commercializing breakthrough medical solutions.
Overall market profit
ARS Pharmaceuticals is developing an intranasal epinephrine spray for the treatment of severe allergic reactions. Like many biotech companies, its success depends on trial results and regulatory approval, not the current economic cycle. However, the overall market situation, reflected in the chart, influences the availability of capital needed to bring the product to market.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company ARS Pharmaceuticals
ARS Pharmaceuticals is developing an intranasal epinephrine spray for the treatment of severe allergic reactions, as an alternative to EpiPen. Future revenue is entirely dependent on FDA approval and a successful product launch. This chart reflects analyst expectations for the commercial potential of this innovative and potentially life-saving product.
%20profit%20of%20the%20company%20ARS%20Pharmaceuticals&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-ARS-Pharmaceuticals&v=1772513491204 "Graph of future (projected) profit of the company ARS Pharmaceuticals")
Future (predicted) profit of companies in the market segment - Pharma other
ARS Pharmaceuticals is developing an intranasal adrenaline spray for the treatment of severe allergic reactions, which could become an alternative to injections. The company's success depends on regulatory approval and market acceptance. This chart shows forecasts for the pharmaceutical sector, helping to assess the potential of ARS's breakthrough product in an industry where innovation is key to growth.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Pharma%20other&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Pharma-other&v=1772513491308 "Graph of future (predicted) profits of companies in a market segment - Pharma other")
Future (predicted) profit of the market as a whole
ARS Pharmaceuticals is developing an intranasal spray containing epinephrine. Like most biopharmaceutical companies in the development stage, its success depends on regulatory approval and market acceptance. The overall economic conditions reflected in this chart are of minimal importance to its near-term prospects.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772513491333 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - ARS Pharmaceuticals
ARS Pharmaceuticals is developing an intranasal epinephrine spray as an alternative to EpiPen. On the cusp of commercialization, the company has minimal revenue. This chart illustrates the market's enormous expectations. Its fluctuations are directly linked to regulatory announcements (the FDA) and reflect the binary bet of approval or rejection of the product.
P/S market segment - Pharma other
ARS Pharmaceuticals is developing an intranasal epinephrine spray for the treatment of severe allergic reactions (anaphylaxis). Future revenue depends on the approval and commercial success of this product. This pharmaceutical sector chart provides an overview of investor expectations regarding ARS's potential to change the standard of anaphylaxis treatment by offering a needle-free alternative.
P/S of the market as a whole
ARS Pharmaceuticals is developing an intranasal epinephrine spray for the treatment of severe allergic reactions (anaphylaxis), which could become an alternative to EpiPen injections. The company's valuation depends on its success in obtaining regulatory approval. This market revenue valuation chart helps understand how investors view the product's potential to change the standard of care.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company ARS Pharmaceuticals
ARS Pharmaceuticals is developing an intranasal epinephrine spray for the treatment of severe allergic reactions, which could become an easy-to-use alternative to EpiPen. This chart shows how the market views the future sales of this potentially revolutionary product. It reflects investor expectations regarding its regulatory approval and commercial success.
%20P%2FS%20ARS%20Pharmaceuticals&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-ARS-Pharmaceuticals&v=1772513491412 "The graph of the company's future (projected) P/S ARS Pharmaceuticals")
Future (projected) P/S of the market segment - Pharma other
ARS Pharmaceuticals is developing an intranasal epinephrine spray (neffy) for the emergency treatment of severe allergic reactions (anaphylaxis), which could become a needle-free alternative to the EpiPen. The company's valuation reflects the enormous market potential of this product, but also the regulatory risks associated with obtaining final FDA approval.
%20P%2FS%20market%20segment%20graph%20-%20Pharma%20other&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Pharma-other&v=1772513491448 "Future (projected) P/S market segment graph - Pharma other")
Future (projected) P/S of the market as a whole
ARS Pharmaceuticals is developing an intranasal adrenaline spray for the emergency treatment of severe allergic reactions. This is a potentially revolutionary product. Revenue growth projections reflected here are subject to change if such innovations change the standards of first aid.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772513491463 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales ARS Pharmaceuticals
ARS Pharmaceuticals is a biopharmaceutical company developing non-invasive treatments for severe allergic reactions. Its lead product is an epinephrine nasal spray. While the company is in the approval stage, it does not yet have commercial revenue, and any revenue shown in the chart may be related to partnerships.
Sales of companies in the market segment - Pharma other
ARS Pharmaceuticals (SPRY) is developing neffy®, an intranasal spray, as an alternative to epinephrine injections (EpiPen) for the emergency treatment of severe allergic reactions. This could dramatically simplify first aid. This chart shows revenue for the pharmaceutical sector, where ARS's innovative product targets a huge market and could change the standard of care for anaphylaxis.
Overall market sales
ARS Pharmaceuticals is developing an intranasal adrenaline spray for the emergency treatment of severe allergic reactions. While demand for such a vital product is not dependent on economic cycles, the overall economic situation, as reflected in the graph, impacts the healthcare system. Stable funding and insurance coverage make innovative drugs more accessible.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company ARS Pharmaceuticals
ARS Pharmaceuticals is developing an intranasal epinephrine spray for the treatment of severe allergic reactions (anaphylaxis). The company's future revenue depends on FDA approval and successful commercialization of this nebulizer product. This chart reflects analyst sales forecasts, which are a bet on the success of their innovative and convenient drug delivery method.
%20sales%20of%20the%20company%20ARS%20Pharmaceuticals&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-ARS-Pharmaceuticals&v=1772513491630 "Schedule of future (projected) sales of the company ARS Pharmaceuticals")
Future (projected) sales of companies in the market segment - Pharma other
ARS Pharmaceuticals is developing an intranasal epinephrine spray (neffy) as a needle-free alternative to EpiPen for the treatment of severe allergic reactions. The forecast in this chart reflects the potential future revenue from this product. This is an analyst's perspective on the commercial prospects of this long-awaited innovation.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Pharma%20other&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Pharma-other&v=1772513491658 "Schedule of future (projected) sales of companies in the market segment - Pharma other")
Future (projected) sales of the market as a whole
ARS Pharmaceuticals is a pharmaceutical company developing an intranasal epinephrine spray for the treatment of severe allergic reactions (anaphylaxis). The company's success depends on regulatory approval and commercial launch. This schedule, reflecting the overall economic situation, influences pricing policy and the speed of introduction of new life-saving drugs.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772513491707 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality ARS Pharmaceuticals
ARS Pharmaceuticals is developing an intranasal epinephrine spray for the treatment of severe allergic reactions, which could become an alternative to EpiPen. While seeking FDA approval, the company is incurring significant research costs. The chart below shows the current profitability, which depends entirely on the future commercial success of this innovative product.
Market segment marginality - Pharma other
ARS Pharmaceuticals is the biopharmaceutical company that developed neffy, the first epinephrine nasal spray for the treatment of severe allergic reactions. This chart depicts its path to profitability. Following FDA approval, the company's success will depend on the successful commercialization of the product and its acceptance by patients and physicians as an alternative to EpiPen.
Market marginality as a whole
ARS Pharmaceuticals is developing an intranasal epinephrine spray for the treatment of severe allergic reactions. As a development-stage company, it has no revenue and relies on investments. This total return chart reflects investor sentiment. During periods of economic growth and high margins, it is easier to raise capital to complete clinical trials and bring the product to market.
Employees in the company, segment and market as a whole
Number of employees in the company ARS Pharmaceuticals
ARS Pharmaceuticals is a biopharmaceutical company developing an intranasal spray for severe allergic reactions. As the product nears approval and launch, its team is growing. This chart shows how the company is hiring sales and marketing specialists to prepare for market launch.
Share of the company's employees ARS Pharmaceuticals within the market segment - Pharma other
ARS Pharmaceuticals is developing an adrenaline nasal spray that could become an easy-to-use alternative to EpiPen. The company is actively building its team as it prepares to launch the product. This timeline reflects its investment in human capital to conduct final trials, obtain regulatory approval, and build the commercial infrastructure.
Number of employees in the market segment - Pharma other
ARS Pharmaceuticals is developing an intranasal adrenaline spray for the treatment of severe allergic reactions. The employment dynamics in the pharmaceutical industry, shown in this graph, illustrate the overall scale of the industry. For ARS, as a niche player, growth in the sector means having a well-developed infrastructure for clinical trials and regulatory processes.
Number of employees in the market as a whole
ARS Pharmaceuticals is a biopharmaceutical company specializing in the development of treatments for severe allergic reactions. Its growth is driven by clinical success and regulatory approvals. The company recruits specialized talent, competing in a broader labor market to advance its innovative solutions.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company ARS Pharmaceuticals (SPRY)
ARS Pharmaceuticals is developing an intranasal adrenaline spray for the treatment of severe allergic reactions. This could become an alternative to EpiPen. The business is focused on a single breakthrough product. This figure reflects the enormous value the market places on the potential of this single product, developed by a small but effective team.
%20of%20the%20company%20ARS%20Pharmaceuticals%20(SPRY)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-ARS-Pharmaceuticals-SPRY&v=1772513492012 "Chart of market capitalization per employee (in thousands of dollars) of the company ARS Pharmaceuticals (SPRY)")
Market capitalization per employee (in thousands of dollars) in the market segment - Pharma other
ARS Pharmaceuticals is developing an intranasal epinephrine spray as an alternative to EpiPen. This is a potentially breakthrough product. The company's high market capitalization per employee reflects market expectations for the commercialization of this innovation. The chart illustrates the enormous future value investors are placing on the work of this small research team.
%20by%20market%20segment%20-%20Pharma%20other&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Pharma-other&v=1772513492034 "Market capitalization per employee (in thousands of dollars) by market segment - Pharma other")
Market capitalization per employee (in thousands of dollars) for the overall market
ARS Pharmaceuticals is developing an intranasal epinephrine spray for the treatment of severe allergic reactions. The chart shows the market valuation of a company whose success depends on a single key product. The high cost per employee reflects the potential market-changing value of this drug, not the current headcount.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772513492068 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company ARS Pharmaceuticals (SPRY)
ARS Pharmaceuticals (SPRY) is a biopharmaceutical company that developed Neffy, an epinephrine nasal spray (an alternative to EpiPen). Following recent FDA approval, the company is transitioning from R&D to commercialization. This timeline will demonstrate how effectively a small team can scale up manufacturing and marketing to generate revenue from this innovative product.
%20Chart%20ARS%20Pharmaceuticals%20(SPRY)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-ARS-Pharmaceuticals-SPRY&v=1772513492073 "Company Profit Per Employee (in thousands of dollars) Chart ARS Pharmaceuticals (SPRY)")
Profit per employee (in thousands of dollars) in the market segment - Pharma other
ARS Pharmaceuticals (SPRY) is a biopharmaceutical company that developed Neffy, an intranasal adrenaline (epinephrine) spray for the treatment of severe allergic reactions. The company is on the cusp of commercialization. This metric (currently negative) reflects R&D and preparation costs for the product's launch.
%20in%20the%20market%20segment%20-%20Pharma%20other&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Pharma-other&v=1772513492081 "Chart of profit per employee (in thousands of dollars) in the market segment - Pharma other")
Profit per employee (in thousands of dollars) for the market as a whole
ARS Pharmaceuticals (SPRY) is a biopharmaceutical company that developed neffy, an epinephrine nasal spray (an alternative to EpiPen). This innovative product targets the vast allergy market. While awaiting FDA approval, there may be no profit. This chart is important to understand that in biotech, the value of an employee is not based on current profits, but on the commercialization potential of a breakthrough product.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772513492096 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee ARS Pharmaceuticals (SPRY)
ARS Pharmaceuticals is developing an intranasal epinephrine spray for the treatment of severe allergic reactions. While the company is currently seeking regulatory approval, it has no commercial revenue yet. This graph shows zero revenue, and its future growth depends entirely on the successful launch of this vital product.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-ARS-Pharmaceuticals-SPRY&v=1772513492109 "Sales chart per company employee ARS Pharmaceuticals (SPRY)")
Sales per employee in the market segment - Pharma other
ARS Pharmaceuticals (SPRY) is the pharmaceutical company that developed neffy, a nasal spray containing epinephrine for the treatment of severe allergic reactions (anaphylaxis). This chart shows the average revenue per employee in the segment. It helps assess how effectively SPRY's team is preparing to commercialize its product.
Sales per employee for the market as a whole
ARS Pharmaceuticals (SPRY) is a biopharmaceutical company in the late-stage development of neffy, an intranasal epinephrine spray for the treatment of severe allergic reactions. Revenue is currently minimal, but the company is preparing for commercialization. This metric reflects current personnel costs. If approved by the FDA, it should skyrocket, demonstrating the effectiveness of monetizing the product.
Short shares by company, segment and market as a whole
Shares shorted by company ARS Pharmaceuticals (SPRY)
ARS Pharmaceuticals (SPRY) is a biotech company whose main development is an intranasal spray (neffy) for the treatment of severe allergic reactions (anaphylaxis), as an alternative to EpiPen. This chart shows short interest. The surge in short bets is likely related to the FDA's initial decision to deny approval, requiring additional data, which creates uncertainty. (346)
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-ARS-Pharmaceuticals-SPRY&v=1772513492172 "Short Shares Chart for the Company ARS Pharmaceuticals (SPRY)")
Shares shorted by market segment - Pharma other
ARS Pharmaceuticals is developing Neffy, an intranasal adrenaline spray for the emergency treatment of severe allergic reactions (anaphylaxis). This chart reflects the overall sentiment in the sector. It reflects investor skepticism toward biotechs attempting to bring to market (and gain FDA approval) a new delivery method for an old drug.
Shares shorted by the overall market
ARS Pharmaceuticals (SPRY) is developing a needle-free epinephrine spray. It's a promising product, but its fate depends on FDA approval. When this chart shows rising fear, investors are unwilling to take on binary (approval/disapproval) risk. They prefer to sell speculative biotechs and wait out the panic in more predictable assets.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator ARS Pharmaceuticals (SPRY)
ARS Pharmaceuticals (SPRY) is a biopharmaceutical company that developed neffy, an intranasal epinephrine spray for the treatment of severe allergic reactions (anaphylaxis). It is a potential replacement for EpiPen. This chart measures hype. It shows "overbought" (above 70) on expectations of FDA approval or "oversold" (below 30) on news of regulatory delays.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-ARS-Pharmaceuticals-SPRY&v=1772513492204 "RSI 14 indicator chart for the company's stock ARS Pharmaceuticals (SPRY)")
RSI 14 Market Segment - Pharma other
ARS Pharmaceuticals (SPRY) is a biopharmaceutical company that developed neffy, an adrenaline nasal spray for the treatment of severe allergic reactions (anaphylaxis). This chart tracks overall sentiment in the Pharmaceuticals sector. It helps investors understand whether SPRY's performance reflects its regulatory path or whether the entire sector is overheated or oversold.
RSI 14 for the overall market
ARS Pharmaceuticals (SPRY) is a biotech company. Like everything in its sector, it's critically dependent on this chart. Market euphoria is an opportunity to easily raise hundreds of millions of dollars for research. Market panic is the risk of running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast SPRY (ARS Pharmaceuticals)
ARS Pharmaceuticals (SPRY) is a biopharmaceutical company that developed "neffy," an intranasal epinephrine spray for the treatment of severe allergic reactions (anaphylaxis) as an alternative to EpiPen. This chart shows the average analyst price target, contingent on FDA approval.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-SPRY-ARS-Pharmaceuticals&v=1772513492255 "A chart showing analyst consensus forecasts for the expected stock price. SPRY (ARS Pharmaceuticals)")
The difference between the consensus estimate and the actual stock price SPRY (ARS Pharmaceuticals)
ARS Pharmaceuticals (SPRY) is the biopharmaceutical company behind Neffy, the world's first epinephrine nasal spray, designed to replace the EpiPen (an injection) for treating severe allergic reactions (anaphylaxis). This chart shows analysts' confidence in the approval and commercial success of this convenient product.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-SPRY-ARS-Pharmaceuticals&v=1772513492264 "A chart showing the difference between the consensus forecast and the actual stock price. SPRY (ARS Pharmaceuticals)")
Analyst consensus forecast for stock prices by market segment - Pharma other
ARS Pharmaceuticals (SPRY) is a biopharmaceutical company whose flagship product, neffy, is an epinephrine nasal spray, an alternative to the EpiPen (an injection) for treating severe allergies. This chart shows analysts' overall expectations for the pharmaceutical sector, reflecting whether experts believe there will be demand for "needle-free injections."
Analysts' consensus forecast for the overall market share price
ARS Pharmaceuticals (SPRY) is a biopharmaceutical company developing an intranasal spray (neffy) for the emergency treatment of severe allergic reactions (anaphylaxis), as an alternative to EpiPen. This chart shows the overall risk appetite. For ARS, whose value depends on regulatory approval, overall market optimism is important for funding the commercialization process.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index ARS Pharmaceuticals
ARS Pharmaceuticals (SPRY) is a company that wants to kill the EpiPen. Their flagship product, "neffy," is an epinephrine nasal spray designed for the emergency treatment of severe allergies (anaphylaxis) without the need for a needle. This chart is essentially a binary bet. It reflects their long battle with the FDA for approval and the market's belief that their spray can capture the multibillion-dollar pen market.
AKIMA Market Segment Index - Pharma other
ARS Pharma (SPRY) is a single-product biotech company that created the world's first (and only) nasal spray (Neffy) with epinephrine—a needle-free alternative to EpiPen for treating severe allergies. This summary metric evaluates R&D. The graph shows the segment average. This benchmark: how does this breakthrough (spray instead of injection) model (SPRY) differentiate it from the average pharma company?
The AKIM Index for the overall market
ARS Pharmaceuticals is a company that developed a nasal spray (neffy) for the treatment of severe allergic reactions (anaphylaxis) as an alternative to injections. This chart, reflecting the market average, provides a macro backdrop. It helps assess how this commercialization of a convenient solution for patients compares to overall economic trends.
